| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism BC2L-C-Nt inhibitors(BC2L-C-Nt (B. cenocepacia) inhibitors), LecB inhibitors(LecB (P. aeruginosa) inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC19H21NO5 | 
| InChIKeyKFRIUGARMXQWFO-QFFBLRJASA-N | 
| CAS Registry2883775-31-1 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Burkholderia Infections | Preclinical | Italy  | 25 Apr 2025 | |
| Pseudomonas aeruginosa infection | Preclinical | Italy  | 25 Apr 2025 | 





